Document Detail

Randomized controlled trials on the therapeutic effects of adult progenitor cells for myocardial infarction: meta-analysis.
MedLine Citation:
PMID:  20384520     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: We performed a systematic meta-analysis to assess the therapeutic effects of progenitor cell therapy after myocardial infarction (MI). RESEARCH DESIGN/METHODS: Randomized controlled trials of progenitor cell therapy for MI were extracted from MEDLINE. We performed a prospective comparison of progenitor cell therapy versus placebo after acute or chronic MI, with changes in left ventricular ejection fraction (LVEF) as the primary endpoint. We conducted random-effects meta-analyses to pool these outcomes across the studies. RESULTS: A total of 980 patients from 18 studies were analysed. Seventeen trials used bone marrow-derived cells (BMCs). Overall, BMCs significantly increased LVEF, left ventricular end systolic volume and left ventricular end diastolic volume within six months of treatment, and the effect was sustained one year later. Following BMC transplantation regional myocardial anatomy displayed statistically and clinically significant improvements compared with controls, albeit without functional changes. Similar results were observed in the subgroup of patients with impaired LVEF at the baseline. The subgroup analysis suggested a benefit of BMCs on LVEF in acute but not chronic MI. LVEF enhancement seemed to correlate positively with dose and inversely with the storage duration of the BMCs. CONCLUSIONS: BMC transplantation for MI was able to deliver benefits over regular therapy even at an 18-month follow-up, particularly when used to treat acute MI. CD34(+) cell therapy holds promise for MI treatment in the future.
Meng Jiang; Ben He; Qi Zhang; Heng Ge; Ming H Zang; Zhi H Han; Jian P Liu; Jin H Li; Qing Zhang; Hong B Li; Yan Jin; Qing He; Xin R Gong; Xiao Y Yin
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  10     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-13     Completed Date:  2010-07-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  667-80     Citation Subset:  IM    
Department of Cardiology, Shanghai Jiaotong University, Renji Hospital, School of Medicine, Shanghai 200001, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adult Stem Cells / immunology,  transplantation*
Antigens, CD34 / analysis
Evidence-Based Medicine
Middle Aged
Myocardial Infarction / pathology,  physiopathology,  surgery*
Myocardium / pathology*
Randomized Controlled Trials as Topic*
Recovery of Function
Stroke Volume
Time Factors
Treatment Outcome
Ventricular Function, Left
Reg. No./Substance:
0/Antigens, CD34

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  In vitro biological studies and structural elucidation of fluoro-substituted phenyl acrylic acids.
Next Document:  Mesenchymal stem cell therapy for the treatment of chronic obstructive pulmonary disease.